The mTOR inhibitor Everolimus has been tested in Phase 1 clinical trials for targeting glutamatergic signaling for Autism Spectrum Disorders (ASDs) and Temsirolimus have similarly been reported to be used in rodents for altering mTORpathway90–92. The gene discussed is MTOR; the disease is autism spectrum disorder.